Bristol Myers Squibb (CELG-RI) EBIT (2009 - 2026)

Bristol Myers Squibb has disclosed EBIT across 18 years of filings, most recently posting -$182.0 million for Q1 2026.

• In Q1 2026, EBIT fell 193.55% year-over-year to -$182.0 million; the TTM figure through Mar 2026 stood at -$4.7 billion (up 40.6% YoY), while the FY2025 annual figure was -$4.6 billion, up 79.38% from the prior year.
• EBIT climbed to -$182.0 million in Q1 2026, from -$2.6 billion in the prior quarter.
• Over the last five years, EBIT for CELG-RI reached as high as $204.0 million in Q1 2023 and fell as low as -$14.4 billion in Q1 2024.
• The 5-year median for EBIT is -$784.0 million (2022), against an average of -$1.9 billion.
• Annual changes were most pronounced in 2023 — EBIT surged 126.02% — and 2024, when it sank 7182.35%.
• A 5-year view of EBIT shows it stood at -$734.0 million in 2022, then plunged by 45.91% to -$1.1 billion in 2023, then tumbled by 332.96% to -$4.6 billion in 2024, then surged by 43.35% to -$2.6 billion in 2025, then jumped by 93.07% to -$182.0 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$182.0 million, -$2.6 billion, and -$321.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.